SAN DIEGO, March 20, 2014 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the appointment of Vickie Capps to the company's board of directors. Ms. Capps will assume the position of chair of the audit committee.
Ms. Capps previously served as executive vice president, chief financial officer and treasurer for DJO Global Inc., a global provider of medical devices and services that provide solutions for musculoskeletal health, vascular health and pain management. Her leadership in corporate finance and role on the senior management team supported consistent growth over her 11 year tenure with the company, including revenue growth from $182 million in 2002 to over $1.1 billion in 2013. She also led more than ten acquisitions and one merger. Earlier in her career, Ms. Capps spent 10 years with Ernst & Young as a senior audit and accounting professional. She currently serves on the board of directors for RF Surgical Systems and the Senior Advisory Board of Consonance Capital Partners, and previously served on the board of directors for publicly traded SenoRx until its acquisition by C. R. Bard, Inc. Ms. Capps received her bachelor's degree in business administration/accounting from San Diego State University and is a certified public accountant.
"Vickie brings a depth of operational experience related to public company accounting matters, SEC financial reporting and compliance, and dynamics of the public capital markets that will be invaluable to Otonomy's board of directors and management team as we move forward in the execution of our business plan," said David A. Weber, Ph.D., president and CEO of Otonomy. "Furthermore, her track record in supporting the rapid growth of a fully-integrated, international healthcare company is highly relevant to our ongoing efforts to prepare for commercialization."
Otonomy is a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic (IT) injection. Otonomy has three product candidates in development. OTO-201 is an antibiotic that is in Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. OTO-104 is a steroid that is in the first of two pivotal clinical studies (http://menierestudy.info) for the treatment of patients with Ménière's disease. OTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For more information please visit: www.otonomy.com.
Robert H. Uhl
Logo - http://photos.prnewswire.com/prnh/20130806/MM59802LOGO
SOURCE Otonomy, Inc.